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New Stent Technologies 
Yukio Ozaki, Andonis G. Violaris, and Patrick W. Serruys 
Coronary stents were developed to overcome the two 
main limitations of balloon angioplasty, acute occlu- 
sion and long-term restenosis. Coronary stents can 
tack back intimal flaps and seal the dissected vessel 
wall, thereby treating acute or threatened vessel clo- 
sure after unsuccessful balloon angioplasty. After suc- 
cessful balloon angioplasty, stents can prevent late 
vessel remodeling (chronic vessel recoil} by mechani- 
cally enforcing the vessel wall and resetting the vessel 
size, resulting in a low incidence of restenosis. All 
currently available stents are composed of metal, and 
the long-term effects of their implantation in the 
coronary arteries are still not clear. Because of the 
metallic surface, they are also thrombogenic; there- 
fore, rigorous antiplatelet or anticoagulant therapy is 
theoretically required. Furthermore, they have an im- 
perfect compromise between scaffolding properties 
and flexibility, resulting in an unfavorable interaction 
between stents and unstable or thrombus-laden 
plaque. Finally, they still induce substantial intimal 
hyperplasia that may result in restenosis. Future stents 
can be made less thrombogenic by modifying the 
metallic surface or coating it with an antithrombotic 
agent or a membrane eluting an antithrombotic drug. 
The unfavorable interaction with the unstable plaque 
and the thrombus burden can be overcome by cover- 
ing the stent with a biological conduit, such as a vein, 
or a biodegradable material that can be endogenous, 
such as fibrin, or exogenous, such as a polymer. 
Finally, the problem of persisting induction of intimal 
hyperplasia may be overcome with the use of either a 
radioactive stent or a stent eluting an antiproliferative 
drug. 
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C ORONARY stents were developed to over- come the two main limitations of balloon 
angioplasty, acute occlusion and long-term reste- 
nosis. Coronary stents can tack back intimal 
flaps and seal the dissected vessel wall, thereby 
treating acute or threatened vessel closure after 
unsuccessful balloon angioplasty. After success- 
ful balloon angioplasty, stenting can prevent 
late vessel remodeling (chronic vessel recoil) by 
mechanically enforcing the vessel wall and reset- 
ting the vessel size, resulting in a low incidence 
of restenosis. These theoretical advantages of 
coronary stenting have been tested in two major 
randomized trials. 1,2 Both the Belgium Nether- 
lands Stent Study (Benestent) and Stent Reste- 
nosis Study (STRESS) confirmed the theoreti- 
cal advantages of coronary stenting by showing 
a reduction in angiographic restenosis and clini- 
cal events during follow-up examination. 1,2 This 
reduction in restenosis was achieved by a greater 
luminal gain despite the accommodation of a 
greater absolute loss in lumen diameter in the 
stent group, suggesting greater neointimal hyper- 
plasia in this group. The reduction in long-term 
restenosis was counterbalanced by bleeding com- 
plications related to the anticoagulant therapy. 
Therefore, a number of limitations have to be 
overcome before coronary stenting achieves its 
full potential. 
CURRENTLY AVAILABLE STENTS 
The currently available stents, a description 
of their design, and the year of their clinical 
introduction are listed in Table i and are shown 
in Fig 1. In the absence of prospective random- 
ized interstent comparative trials, it is difficult 
to draw conclusions on the relative merits and 
demerits of each stent design. However, indi- 
vidual experience and registry data from each 
stent allow preliminary impressions to be made 
on the advantages and limitations of each stent. 
Wallstent 
The Wallstent (Schneider, Bulach, Switzer- 
land) was the pioneer of stents 34 through which 
we learned the risk profile and indications for 
coronary stenting and the necessity and adverse 
effects of antithrombotic measures. The new 
less-shortening Wallstent has been developed 
recently with a change in the braiding angle, 
and results of the first clinical implantation of 
this second generation stent in coronary vein 
grafts have been promising. 6 The unique advan- 
tages of the Wallstent include the extensive 
range of diameters and lengths available, thereby 
allowing the Wallstent o be used for the man- 
agement of long spiral dissections 7 and for 
vessel reconstruction) The sheathed "balloon- 
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Table 1. Currently Available Stunts Undergoing Clinical Evaluation 
Diameter Length First Clinical 
Coronary Stent Design Deployment Premounted Delivery (mm) (mm) Implantation 
Wallstent Wire mesh Self-expanding Balloon Over-the-wire 3,5-6.0 12-42 1986 
not required 1991 (less- 
shortening) 
Palmaz- Slotted tube Balloon-expandable Premounted Over-the-wire 3.0-4.0 8-18 1988 
Schatz and unmounted and both 1994 (heparin- 
coated) 
Gianturco- Incomplete coil Balloon-expandable Premounted Over-the-wire 2.5-4.0 20-40 1989 (GR-I) 
Roubin clam-shell loop 1995 (GR-II) 
Wiktor Sinusoidal Balloon-expandable Premounted Over-the-wire 3.0-4.5 16 t991 
helical coil or monorail 1995 (short- 
wave) 
Multi-Link Multiple rings with Balloon-expandable Premounted Over-the-wire 3.0-3.5 15 1993 
multiple links 
Cordis Sinusoidal Balloon-expandable Premounted Over-the-wire 3.0-4.0 15 1994 
helical coil 
AVE Micro Zigzag axial Balloomexpandable Premounted Monorail 2.5-4.0 6-36 1994(Micro-I) 
struts 1995 (Micro-II) 
Expandable uniform Balloon-expandable Unmounted 2.0-5.0 9-32 1995 
cellular mesh 
NIR Both 
less" delivery system in combination with the 
free, unconnected wire-mesh design, render the 
Wallstent one of the most trackable, pushable, 
and flexible stents for negotiating tortuous ves- 
sel and passing through proximally deployed 
stents (Fig 2). Furthermore, recent modification 
of the delivery system allows recapture of the 
stent before final deployment and also allows 
Fig 1. Coronary stents that have undergone clinical evaluation are shown clockwise from the left: Wallstent, Palmaz-Schatz, 
Wiktor, Gianturco-Roubin, Cordis, AVE Micro, and ACS Multi-Link. (Reprinted with permission. ~) 
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Fig 2. (A) Long complex stenosis in left anterior descending artery before intervention. (B) Final angiographic outcome after the 
deployment of the new less-shortening Wallstent, Note the smooth contour stented segment with no loss of side branches and the 
absence of vessel sprinting that may be obseved after the deployment of a more rigid stent. 
improved positioning, raising the possibility for 
the use of shorter Wallstents in clinical practice. 
Its fine cross-hatched mesh design provides 
excellent scaffolding properties particularly well- 
suited to entrap friable material in diffusely 
diseased vein grafts. Additionally, enforced me- 
chanical remodeling produced by oversizing 
Wallstent implantation conveys a favorable 
6-month clinical and angiographic outcome in 
both stenosis and total occlusions in native 
coronary arteries. 74 Its primary limitations are 
the longitudinal shortening of the stent on 
radial expansion and motion of the stent during 
retraction of the rolling membrane, thus render- 
ing the stent less suitable for ostial esions. 
Palmaz-Schatz Stent 
The Palmaz-Schatz stent (Johnson & Johnson 
Interventional Systems, Warren, N J) has been 
extensively investigated in a broad range of 
coronary lesions. 9-18 It is the only stent o date to 
have completed prospective randomized trials 
comparing the clinical and angiographic out- 
come with that of balloon angioplasty. 1,zThe 
angiographic results after Palmaz-Schatz stent 
implantation are predictable, and the slotted- 
tube design allows the performance of high- 
pressure intrastent balloon inflations without 
risk of structural deformation. However, the 
low radiopacity of the Palmaz-Schatz stent can 
render the positioning of a noncompliant baI- 
loon for postdeployment, high-pressure, intra- 
stent inflations difficult. Additionally, a higher 
incidence of restenosis has been reported at the 
site of the central articulation. 19 To overcome 
this limitation, a recent model has been devel- 
oped without the central articulation (spiral 
articulation design). This model has a higher 
radiopacity compared with that of the standard 
single articulation design. The availability of a 
free, unmounted Palmaz-Schat~z stent that can 
be crimped by the operator on any balloon 
provides more procedural versatility and results 
in a lower profile during stent delivery. How- 
ever, it does increase the risk of losing the stent 
during deployment. 
Gianturco-Roubin Stent 
Before obtaining Food and Drug Administra- 
tion (FDA) approval for noninvestigational clini- 
cal use, most of the clinical data on the Giant- 
urco-Roubin stent (Cook, ]nc, Bloomington, 
IN) was gathered in single and multicenter 
registries in the United States. 2°-25 The indica- 
tion for the Gianturco-Roubin stent for which 
most data have been gathered is for the bailout 
of subocclusive and occlusive dissections after 
balloon angioplasty in native coronary arteries. 
The data gathered compare well with the data 
from historical controls treated by repeated and 
prolonged balloon angioplasty alone. The re- 
sults of the first randomized trial of the Giant- 
urco-Roubin stent i  bailout herapy (Gianturco- 
Roubin stent in Acute Closure Evaluation 
[GRACE]) are awaited with interest. 26The 
principle advantages of the Gianturco-Roubin 
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stent include its range of lengths and longitudi- 
nal flexibility. Although the relatively large 
interstrut intervals of 1 mm raise questions over 
the suitability of this stent for the management 
of friable vein graft lesions, the advantages of 
the Gianturco-Roubin stent design include mini- 
mal risk of "jailing" side branches and the 
potential to perform coronary interventional 
procedures in side branches through the inter- 
strut spaces. Whereas this stent excels in long 
dissections in curved coronary segments (Fig 3), 
its more generalized use was hindered by the 
high profile of the first generation. The new 
Fig 3. (A) Dissection after balloon angioplasty in the proxi- 
mal left anterior descending artery is shown. (B) After delivery 
of a Gianturco-Roubin Flexstent through a Superflow 8-French 
Judkins guiding catheter (Cordis) to the target vessel, the 
radiopaque markers (located 1 mm proximal and distal to the 
stent extremities) facilitate the final positioning of the stent 
before inflation of the delivery balloon. (C) Contrast angiogra- 
phy poststent deployment shows preservation of the vessel 
curvature in the stented segment. (Reprinted with permis- 
sion. z ) 
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generation flex-II stent overcomes these prob- 
lems with a lower profile and a higher visibility. 
Wiktor Stent 
The available clinical data on the Wiktor 
stent (Medtronic, Minneapolis, MN) arises from 
observational studies and registry data, 273° the 
principle registry of which has been in the 
management of restenotic lesions. Similar to 
the Gianturco-Roubin stent, the Wiktor stent is 
a coil stent that offers marked flexibility and, 
thus, conformability with the vessel curvature. 
However, also similar to the Gianturco-Roubin 
stent, the Wiktor stent is unlikely to excel in the 
treatment of friable vein grafts because of the 
large interstrut interval and the subsequently 
reduced scaffolding properties. The radiopacity 
of the Wiktor stent allows exquisite positioning 
of the stent in ostial and focal lesions, and the 
flexibility of the stent makes it suitable for short 
dissections on curved coronary segments. The 
recent introduction of the option of a monorail 
delivery system improves the user-friendliness 
of the device. The limitations of the initial 
prototype of the Wiktor stent included the 
availability of only one length and the limited 
scaffolding properties with the potential for the 
protrusion of intimal flaps through the inter- 
strut intervals. These limitations have been 
overcome by the new generation, short-wave- 
form Wiktor stent, although the radiopacity of 
this tantalum stent can still interfere with on- 
line quantitative angiographic analysis of the 
stented segmentP 1 
Multi-Link Stent 
At present, the ACS Multi-Link stent (Ad- 
vanced Cardiovascular Systems, London, UK) 
has the least clinical experience of the currently 
available stents, having just completed its first 
100-patient registry conducted at five European 
centers. 3z The advantages of this new stent 
include the flexibility and low profile of the 
sheathed stent and delivery system. Although 
the Multi-Link stent design manages to provide 
remarkable scaffolding properties, the metallic 
burden to the stented vessel remains very low by 
virtue of the small diameter of the corrugated 
struts. The limitations of the stent include its 
radiolucency, which renders the positioning of 
noncompliant balloons for postdelivery, high- 
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pressure intrastent inflations very difficult. The 
current availability of only one length of 15 mm 
means that the first prototype can only be used 
for very focal lesions. After some minor modifi- 
cations, this stent may offer some significant 
advantages over the earlier generation of stent 
designs. The attachment of radiopaque tips on 
the stent would present a significant enhance- 
ment. 
AVE Micro Stent 
The AVE Micro stent (Applied Vascular 
Engineering, Santa Rosa, CA) is now undergo- 
ing clinical evaluation in a large number of 
countriesY The high degree of radiopacity and 
balloon-expandable deployment should render 
this stent ideal for exquisite positioning in 
highly focal and ostial esions (Fig 4). However, 
by virtue of the longitudinal (axial) orientation 
of its eight struts, the 4-mm AVE Micro stent 
units may be prone to proximal migration and 
protrusion; therefore, preferably onger, welded 
AVE Micro stents should bedeployed in ostial 
locations. The customized range of short lengths 
make the AVE Micro stent ideal as an adjunc- 
tive complementary device for multiple stent- 
ing, filling in the gaps between longer stents, 
and improving the inflow or outflow of longer 
stents. Additionally, the high flexibility and low 
thrombogenecity of the AVE micro stent make 
it an ideal stent for bailout management after 
failed balloon angioplasty. 33 Despite the ab- 
sence of a protective sheath, the low profile and 
longitudinal strut orientation make the AVE 
micro stent one of the easiest stents to pass 
through other proximally deployed stents. The 
monorail delivery system increases the user- 
friendliness of the device, which has a short 
learning curve. The strong radial support prof- 
fered by the thick struts should make the stent 
suitable for the prevention of recoil and resteno- 
sis. However, care should be taken to avoid the 
positioning of junctions between the uncon- 
nected 4-ram units at the site of the minimal 
lumen diameter of lesions to prevent intimal 
protrusion. Recent developments include the 
helicoildal welding of multiple 3-mm-length 
units (Micro stent-II) to provide multiple lengths 
of up to 36 ram. 
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Fig 4. (A) Short dissection in the origin of the left circum- 
flex coronary artery after balloon angioplasty is shown. (B} An 
AVE Micro stent is delivered to the target vessel through an 
8-French Amplatz guiding catheter (Schneider Scientific, Wa- 
tertown, MA). The two radiopaque markers at the extremities 
of the stent are clearly seen. (C) After delivery of the stent, the 
thick radiopaque stainless-steel struts facilitate the precise 
positioning of a short noncompliant balloon (single marker) 
within the stent for subsequent high-pressure inflations and 




The Cordis stent (Cordis, Miami, FL) contin- 
ues to undergo early evaluation in the clinical 
arena? ~ Similar to the ACS stent, the Cordis 
stent offers some advantages over the first 
generation stents by virtue of its low profile, 
flexibility, and comprehensive scaffolding prop- 
erties. However, the absence of a protective 
sheath on the delivery system increases the 
possibility of stent dislodgement or disruption 
during delivery. The operator should be aware 
of the protrusion of the delivery balloon beyond 
the limits of the Cordis stent if inflations of 
higher pressure are considered. Although the 
strongly radiopaque tantalum struts allow exquis- 
ite positioning (Fig 5) of the stent in short 
dissections in curved coronary segments, the 
radiopacity may pose problems for on-line quan- 
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titative angiographic assessment, particularly 
during assessment of luminal renarrowing at 
6-month angiographic follow-up examination. 31 
The relative merits of this stent are currently 
being evaluated in a European multicenter 
registry and by Hamasaki et al in Japan. 34 
NIR Stent 
The NIR stent (Medinol, Tel Aviv, Israel) is a 
recently developed balloon-expandable stent 
currently undergoing clinical evaluation i some 
centers in Israel and Europe. Although t is 
stent has a low radiopacity, the stent has a high 
flexibility and comes in a wide range of custom- 
ized sizes (diameter, 2 to 5 ram) and lengths (9 
to 32 ram). Balloon-unmounted models allow 
for the choice of various types of balloon for 
stent delivery and may spare the usage of an 
i ! ;; i ii~i ¸¸ii;i!! ! I 
Fig 5. (A) The left coronary artery tesion located at the bifurcation is shown, {B) Postballoon angioplasty dissection type C was 
clearly seen. (C) Positioning of the Cordis stent was facilitated by the radiopacity of the tantalum struts, which are clearly seen during 
inflation of the contrast-filled intrastent balloon to 10 atm. (D) Angiography after stent deployment shows the stent struts to be 
embedded in the vessel wall external to the contour of the contrast-filled lumen. 
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additional balloon catheter only for stent deliv- 
ery. A preliminary report indicates a high deploy- 
ment success rate despite the fact that most of 
the lesions were difficult to treat because of 
vessel tortuosity, distal ocation, and long lesion 
length. 35 The restenosis rate has not yet been 
determined. 
FUTURE STENTS 
All currently available stents are composed of 
metal, and the long-term effects of their implan- 
tation in the coronary arteries are still not clear. 
Because of the metallic surface, they are throm- 
bogenic; therefore, rigorous antiplatelet or anti- 
coagulant herapy is theoretically required. 
Furthermore, they represent an imperfect com- 
promise between scaffolding properties and 
flexibility, resulting in an unfavorable interac- 
tion between stent and unstable plaque or 
thrombus burden. Finally, they still induce sub- 
stantial intimal hyperplasia that may result in 
restenosis. Future stents can be made less 
thrombogenic by modifying the metallic surface 
or coating it with an antithrombotic agent or a 
membrane luting an antithrombotic drug. The 
unfavorable interaction with the unstable plaque 
and the thrombus burden can be overcome by 
covering the stent with a biological conduit, 
such as a vein, or a biodegradable material that 
can be endogenous, such as fibrin, or exog- 
enous, such as a polymer. Finally, the problem 
of persisting induction of intimal hyperplasia 
may be overcome with the use of either a 
radioactive stent or a stent eluting an antiprolif- 
erative drug. 
Coated Stents 
Metal coated. In vitro work suggests that 
surface potential may exert a substantial effect 
on both the thrombogenicity and antiprolifera- 
tive effect of metals. High surface potential is 
associated with pronounced attraction of nega- 
tively changed particles such as platelets and 
plasma proteins, thus resulting in high thrombo- 
genicity. Conversely, however, metals with high 
surface potential have a substantial ntiprolifer- 
ative effect on fibroblasts, suggesting that, by 
varying surface charge, we may be able to 
influence the thrombogenicity and neointimal 
hyperplasia fter stent implantation. One way 
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of accomplishing this would be by modifying the 
base metal. 36 
Metals can be  modified either by galvaniza- 
tion or by ion bombardment. Galvanization 
involves the electrochemical deposition of metal 
3.3 p~m in thickness on the stent and results in 
100% of the stent surface being covered before 
stent expansion. Ion bombardment consists of 
spluttering a thin metal film onto the stent 
followed by a bombardment with argon ions. 
The resulting implantation of metal onto the 
stent surface increases the thickness by 20 nm, 
and 75% stent surface coverage is required 
before expansion. 
Preliminary experience suggests that coating 
steel stents with platinum, gold, or copper 
results in higher in vitro surface potentials but 
that the incidence of thrombosis in vivo is 
increased, particularly in stents coated using 
galvanization. 36 Thus, in contrast to the in vitro 
suggestion, metal charge does not seem to play 
a major role in stent thrombogenicity in vivo. 
Furthermore, a low stent charge appeared to 
correlate with increased neointimal formation. 
Therefore, modifying stainless teel stents by 
covering them with gold, platinum, or copper is 
unlikely to be the solution to increased thrombo- 
genicity or neointimal hyperplasia. 
Cell seeding of stents. Coating of metallic 
stents with endothelial cells, particularly geneti- 
cally engineered cells with increased cell sur- 
face fibrinolytic activity, may improve their 
thrombogenic nature. Preliminary work has 
shown the feasibility of this approach. 3v,3s More 
recently, in vitro work suggests that genetically 
engineered endothelial cells would allow in- 
creased fibrinolysis to be promoted by the sur- 
face localization of urokinase. 39However, ques- 
tions remain concerning the number of cells 
that will remain attached under flow conditions 
and the legal responsibility in case of failure of 
endothelial cell function. 
Immobilized rug coatings. Coating of the 
stent surface with an antithrombotic agent such 
as heparin 4°-42 provides a novel solution to the 
problem of increased thrombogenicity of metal- 
lic stents and the subsequent eed for intensive 
anticoagulation that results in increased morbid- 
ity and costs. After encouraging preliminary 
experience with a heparin-coated Palmaz- 
Schatz stent in pig coronary arteries, the Bene- 
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stent-II study evaluated the safety of reducing 
and eliminating anticoagulant therapy in pa- 
tients receiving a heparin-coated stent. Initial 
results from the pilot study suggest hat sub- 
acute stent thrombosis does not occur using the 
heparin-coated stent, which virtually eliminated 
the bleeding complications after stent implanta- 
tion and reduced the in-hospital stay to 3 days. 43 
The 6-month angiographic follow-up examina- 
tion also indicates that these coated stents do 
not induce excess of intimal hyperplasia. 44 The 
results of follow-up studies in which coumadin 
and heparin are replaced by ticlodipine and 
aspirin are awaited. 
Polymer-coated stents. The stent metal sur- 
face can be rendered less thrombogenic by 
coating it with a thin layer of a synthetic 
polymer. Initial results uggested that, although 
this may protect against acute thrombotic events, 
it does not reduce the extent of subsequent 
neointimal hyperplasia. 4s However, the advan- 
tage of a polymer-coated stent is that it can be 
loaded with antithrombotic or antiproliferative 
agents directed against he neointimal repara- 
tive process (Fig 6).46 
Fibrin stent. The fibrin-film stent has several 
theoretical advantages. It is a membrane stent 
and thus can cover the balloon angioplasty 
injury site, thereby providing a natural healing 
matrix while reducing local thrombus forma- 
tion. It may also be useful in vein grafts in which 
Fig 6. An eluting stent consisting of a stent surrounded by 
an elastic sleeve made of biodegradable polymer loaded with 
40% antithrombotic agent is shown, 
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the membrane may prevent distal embolization 
of friable material. Preliminary work suggests 
that the fibrin-film stent is both bioabsorbable 
and biocompatible. 47 It also appears to be safe 
in pigs with the use of an antiplatelet agent. 
However, it had little effect on neointimal 
proliferation. 
Vein-coatedstents. An autologous vein graft- 
coated stent consisting of a conventional stent 
covered by a vein graft may be the ideal conduit 
for percutaneous revascularization, thus mini- 
mizing stent thrombogenicity and local tissue 
reaction to the stent. Preliminary experience in 
13 patients uggests that the technique is fea- 
sible and safe, resulting in an excellent immme- 
diate angiographic result, 4s but further studies 
are warranted to investigate the effect of the 
procedure on subacute thrombosis and long- 
term restenosis. 
Nitinol Stent 
Nitinol has a number of properties that make 
it ideal for stent composition. It is known to be 
highly biocompatible and highly malleable, al- 
lowing 0.006-in struts without sacrificing flexibil- 
ity. Furthermore, it has unique thermoelastic 
properties that allow for stent collapse and 
removal as well as for self-expansion. 4942 Fi- 
nally, it is amenable to surface coating for local 
drug delivery and is transmutable into a radioac- 
tive emitter for local radiation therapy. Prelimi- 
nary work in a pig coronary subacute thrombo- 
sis model has confirmed some of these 
theoretical dvantages ofa nitinol stent showing 
that nitinol stents, particularly polished nitinol 
stents, develop significantly less thrombus (as 
measured by thrombus weight and thrombus 
grade) in comparison with that for stainless 
steel stents of similar design. 49 The results on 
neointimal hyperplasia are still awaited, al- 
though preliminary results from a separate group 
suggest that a self-expanding nitinol stent exerts 
a more favorable ffect on vascular emodeling 
and neointimal formation than does a balloon- 
expandable, tubular, slotted stent. 5° Initial expe- 
rience in 20 patients uggests that a nitinol stent 
is safe and effective in the treatment of subopti- 
mal results. 52 
Polymer Stent 
Polymer stents have several potential advan- 
tages. They can be loaded with antithrombotic 
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and/or antiproliferative pharmaceutical agents 
in high concentration for sustained local deliv- 
ery. They may have less of a mechanical mis- 
match with the vessel wall than do metal stents 
and may avoid the potential for late-stage com- 
plications. Therefore, polymer stents have a 
synergistic mechanical nd local pharmacologi- 
cal effect that provides sustained structural 
support throughout the healing phase, thus 
potentially avoiding early and late elastic recoil 
while the local high-dose drug delivery poten- 
tially prevents thrombosis, neointimal prolifera- 
tion, and systemic side effects. However, there is 
only limited strength if a large percentage of 
drug is loaded onto the stent. Initial animal 
experiments, however, have shown a marked 
inflammatory esponse resulting in substantial 
luminal encroachment with polymer stents in 
porcine coronary arteries, 3,s4 However, there is 
no vascular tissue reaction with high molecular 
weight poly-l-lactic acid, and this remains a 
promising avenue of investigation. 
Composite (Metal-Augmented) Polymer Stents 
Composite polymer stents guarantee a mini- 
mal mechanical mismatch between the stent 
and the vessel wall, leaving a delicate metal 
skeleton after biodegradation. They provide 
protection of tissues from deep strut laceration 
and large amounts of drug (up to 40%) for slow 
local release without affecting hoop strength. 
Such a composite polymeric stent, capable of 
excellent mechanical strength as well high-dose 
local drug delivery, has been developed and 
evaluated in porcine coronary arteries. Prelimi- 
nary histological analysis howed that neointi- 
real hyperplasia and some degree of inflamma- 
tory response were present in all groups. 
Unfortunately, implantation of bicomponent 
stents caused areduction in lumen diameter for 
all designs. Further research will assess the 
relative contributions of stent geometry, poly- 
mer type, and incorporated drug to the overall 
response. 
Radioactive Stents 
Radiation selectively kills proliferating cells 
independent of the stimulus for cell growth. 
Because a major cause of restenosis neointi- 
real hyperplasia secondary to vascular smooth 
muscle cell proliferation, it seems reasonable to
assume that radiation therapy may reduce reste- 
nosis. Multiple animal studies have now con- 
firmed the ability of radiation therapy to inhibit 
neointimal hyperplasia nd reduce resteno- 
sis. 55'56 Radioactive stents have the potential to 
deliver an appropriate dose of radiotherapy to
the area of interest, thus reducing restenosis 
while minimizing the total dose administered to 
the patient. 
Two methods are currently in use. In the first 
method, conventional Palmaz-Schatz stents are 
bombard with ions in a cyclotron and subse- 
quently emit low-dose [3 and -y radiation from 
radioisotopes Co55, 56, 57, Mn52, and Fe55, 
with half-lives between 17.5 hours and 2.7 
years. 57 The radiation is predominantly short 
range, is homogeneously distributed over the 
length and circumference of the stent, and is 
absolutely fixed to the metal. For this reason, 
the stents do not require a license from the 
International Atomic Energy Agency (Vienna, 
Austria). An intimal surface dose rate of 4 
mGy/h results in an integral dose of 180 mGy 
after a period of 100 days. 
Low-dose radioactive stents were found to 
markedly inhibit neointimal hyperplasia n rab- 
bits. Endothelialization f the radioactive stents 
was found to be delayed with macrophages 
being located on top of the radioactive stent 
struts until endothelialization was complete. 
Although the degree of neointimal hyperplasia 
was reduced, it was found, paradoxically, that 
extracellular matrix production increases after 
radioactive stent implantation. 57 
The second method is uses [3 particles.58, 9 13 
Particles (flee electrons) may represent he 
ideal means of local irradiation, p32 is an excel- 
lent candidate for local delivery because the 
maximal range of 13 particles is 3 to 4 mm in 
tissue. It has a desirable half-life of 14.3 days, 
and, once implanted after balloon angioplasty, 
there is no detectable radiation by 4 months, p32 
or other [3 emitters can also be implanted 
directly onto the stent wire. 
Such p32-impregnated stents have been now 
fabricated. In vitro work suggests that very low 
[3-particle activity levels inhibit smooth muscle 
cell growth preferentially within a 5- to 7-mm 
radius of the P3%coated stent wires, whereas 
endothelial cells appear to be much more radio- 
resistant. In vivo animal testing in a porcine 
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restenosis model using low-dose rate p32 stents 
have shown inhibit ion of neoint imal growth. 58 
A P32-coated stent with doses similar to those 
described should be safe in humans. Total-body 
dosimetry to the patient would be less than 
1/1000 that of fluoroscopy during angioplasty. 
Furthermore,  the radiation would be local and 
would not reach any mediastinal tissues. Addi- 
tionally, the radiation to the interventionalist 
will be much less than that occurring with 
fluoroscatter. 
CONCLUSIONS 
The stent represents he second generat ion of
coronary angioplasty. It is a predictable therapy 
for bailout that improves a suboptimal result 
and reduces the risk of restenosis. As a result of 
these advantages, over 40% of coronary interven- 
tional procedures in the current year will in- 
clude stent implantation. However, the cur- 
rently avai lable stents have a number  of 
l imitations that are being addressed. Drug- 
eluting stents that address the problem of the 
small vessel and low-flow situations are on the 
horizon. Covered stents in which a membrane 
acts as an isolating barrier that minimizes local 
thrombus formation and delivers local drug 
therapy are promising. Radioactive stents to 
inhibit local neoint ima formation are another 
promising avenue of investigation. Biodegrad- 
able stents and composite stents are also being 
actively investigated. 
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